New-Generation High-Definition Colonoscopes Increase Adenoma Detection when Screening a Moderate-Risk Population for Colorectal Cancer

This retrospect observational study of 395 patients undergoing colonoscopy as part of the UK Bowel Cancer Screening Programme, demonstrated that the Olympus H290 LUCERA ELITE high-definition colonoscopes improved adenoma detection within the moderate-risk population. Moreover, it did so when used by operators with a higher-than-average baseline adenoma detection rate. Background and Aim: Adenoma detection rate (ADR) is the most important quality indicator for screening colonoscopy, due to its association with colorectal cancer outcomes. As a result, a number of techniques and technologies have been proposed that have the potential to improve ADR. The aim of this study was to assess the potential impact of new-generation high-definition (HD) colonoscopy on ADR within the Bowel Cancer Screening Programme (BCSP). Method: This was a retrospective single-center observational study in patients undergoing an index screening colonoscopy. The examination was performed with either standard-definition colonoscopes (Olympus Q240/Q260 series) or HD colonoscopes (Olympus HQ290 EVIS LUCERA ELITE system) with the primary outcome measures of ADR and mean adenoma per procedure (MAP) between the 2 groups. Results: A total of 395 patients (60.5% male, mean age 66.8 years) underwent screening colonoscopy with 45% performed with HD colonoscopes. The cecal intubation rate was 97.5% on an intention-to-treat basis and ADR was 68.6%. ADR with standard-definition was 63.13%, compared with 75.71% with HD (P =.007). The MAP in the HD group was 2.1 (+/- 2.0), whereas in the standard-definition group it was 1.6 (+/- 1.8) (P =.01). There was no significant difference in withdrawal time between the 2 groups. In the multivariate regression model, only HD scopes (P =.03) and male sex (P =.04) independently influenced ADR. Conclusion: Olympus H290 LUCERA ELITE HD colonoscopes improved adenoma detection within the moderate-risk population. A 12% improvement in ADR might be expected to increase significantly the protection afforded by colonoscopy against subsequent colorectal cancer mortality. (C) 2016 Elsevier Inc. All rights reserved.